Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21742109 | 0.82 | SLC6A2 (0.47) | SLC6A3SLC6A2SLC6A4KCNA5KCNE1 | |
| SCHEMBL2023423 | 0.80 | — | — | |
| SCHEMBL29467531 | 0.80 | — | — | |
| SCHEMBL2457219 | 0.79 | SLC6A3 (0.73) | SLC6A3SLC6A2SLC6A4KCNA5KCNE1 | |
| Fluoride SCHEMBL28181322 | 0.78 | SLC6A2 (0.52) | SLC6A3SLC6A2SLC6A4KCNA5KCNE1 | |
| SCHEMBL6955104 | 0.77 | SLC6A3 (0.52) | SLC6A3SLC6A2SLC6A4KCNA5KCNE1 | |
| SCHEMBL6957054 | 0.77 | SLC6A3 (0.52) | SLC6A3SLC6A2SLC6A4KCNA5KCNE1 | |
| SCHEMBL27285350 | 0.77 | SLC6A3 (0.52) | SLC6A3SLC6A2SLC6A4KCNA5KCNE1 | |
| SCHEMBL21742235 | 0.76 | — | — | |
| SCHEMBL10873700 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101061097-A | Novel gamma secretase inhibitors | SCHERING CORP (US) | 2007-10-24 | — | — | CN | disclosed |
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1663975-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060100427-A1 | Novel Gamma Secretase inhibitors | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2006-05-11 | — | — | US | disclosed |
| CN-1628100-A | Gamma-secretase inhibitors | SCHERING CORP (US) | 2005-06-15 | — | — | CN | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| WO-2005028440-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1472223-A1 | GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-20040048848-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2003066592-A1 | GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | SLC6A3 3733/4885SLC6A2 4363/4885SLC6A4 4744/4885 |
| US-20040048848-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, PSEN1 | SLC6A3 4319/4885SLC6A2 4718/4885SLC6A4 4725/4885 |
| US-20060100427-A1 | Novel Gamma Secretase inhibitors | BACE1, BACE2, PSEN1 | SLC6A3 4365/4885SLC6A2 4687/4885SLC6A4 4742/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | SLC6A3 2118/4885SLC6A2 3577/4885SLC6A4 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.